All Stories

Indian contractor Syngene throws down $37M for Emergent's Baltimore biologics plant

Indian CRDMO Syngene International is paying $36.5 million to acquire Emergent BioSolutions' shuttered Bayview biologics facility in Baltimore. Syngene ultimately plans to invest around $50 million in the site, which is equipped with multiple production lines for monoclonal antibodies.

Mar 10, 2025 - 20:54
 0
Indian contractor Syngene throws down $37M for Emergent's Baltimore biologics plant
Indian CRDMO Syngene International is paying $36.5 million to acquire Emergent BioSolutions' shuttered Bayview biologics facility in Baltimore. Syngene ultimately plans to invest around $50 million in the site, which is equipped with multiple production lines for monoclonal antibodies.
Read More

Tags:

Previous Article

Trump finds unexpected ally in auto union leader over tariffs

Next Article

Grocery Store Wines Have Come a Long Way. These Bottles Prove it.

Related Posts

Regulatory tracker: ARS' allergy nasal spray neffy approved for use in children

Regulatory tracker: ARS' allergy nasal spray neffy appr...

Mar 6, 2025  0

Regulatory tracker: FDA starts new review of Regeneron's bispecific antibody odronextamab

Regulatory tracker: FDA starts new review of Regeneron'...

Feb 27, 2025  0

Bayer CEO Bill Anderson took pay cut in 2024 as company kicked off 3-year restructuring

Bayer CEO Bill Anderson took pay cut in 2024 as company...

Mar 7, 2025  0